Sotalol Use in Cancer Patients on Avastin and Lonsurf
Sotalol would be indicated in this cancer patient to manage arrhythmias, most likely atrial fibrillation or ventricular arrhythmias, which may arise as cardiovascular complications from bevacizumab (Avastin) therapy or as independent cardiac issues in the oncology setting.
Cardiovascular Complications of Bevacizumab
Bevacizumab, a VEGF signaling pathway inhibitor, causes well-documented cardiovascular toxicities including:
- Hypertension (most common)
- Cardiomyopathy and heart failure (2-4% incidence) 12
- Conduction abnormalities 1
- Arterial thromboses and thromboembolism 2
The guideline evidence specifically notes that VSP inhibitors like bevacizumab cause "conduction abnormalities" 1, which would necessitate antiarrhythmic management. When the heart cannot compensate for bevacizumab-induced hypertension, heart failure can develop 1.
Why Sotalol Specifically
Sotalol serves dual purposes in this clinical scenario:
- Antiarrhythmic properties: Beta-blocker with Class III antiarrhythmic activity for atrial fibrillation or ventricular arrhythmias
- Beta-blockade for cardioprotection: Guidelines recommend ACE-inhibitors, ARBs, and beta-blockers for patients with LVEF <50% but ≥40% before and during cardiotoxic treatment 2
- Blood pressure control: Beta-blockade helps manage bevacizumab-induced hypertension, which is critical since aggressive hypertension management prevents heart failure in patients on VSP inhibitors 1
Clinical Context
The combination of trifluridine/tipiracil (Lonsurf) plus bevacizumab is FDA-approved for metastatic colorectal cancer 333. While Lonsurf itself primarily causes hematologic toxicity (neutropenia, anemia, thrombocytopenia) and gastrointestinal effects 34, it does not directly cause cardiac arrhythmias. The cardiovascular risk stems from bevacizumab.
Monitoring Requirements
For patients on bevacizumab with new cardiac symptoms:
- Obtain cardiology consultation immediately 2
- Reassess LVEF 2
- Measure cardiac biomarkers 2
- Evaluate for signs of heart failure: sinus tachycardia, rapid weight gain, dyspnea, peripheral edema 2
Important Caveats
Aggressive hypertension management is mandatory in patients receiving VSP inhibitors to prevent heart failure 1. If sotalol is being used, ensure:
- QTc interval monitoring (sotalol prolongs QT)
- Renal function assessment (sotalol is renally cleared; Lonsurf requires dose reduction in severe renal impairment) 3
- Electrolyte monitoring (hypokalemia/hypomagnesemia increase arrhythmia risk)
The cardiotoxicity from bevacizumab is largely reversible with cessation of therapy and appropriate heart failure treatment 12, so sotalol may be temporary while bevacizumab is held or permanently discontinued depending on arrhythmia severity and cancer treatment options.